209 related articles for article (PubMed ID: 37110810)
1. Characteristics of Seltorexant-Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety.
Ziemichód W; Kurowska A; Grabowska K; Kurowska M; Biała G
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110810
[TBL] [Abstract][Full Text] [Related]
2. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
Fagan H; Jones E; Baldwin DS
CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
[TBL] [Abstract][Full Text] [Related]
4. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
[TBL] [Abstract][Full Text] [Related]
5. Orexin Receptor Antagonists and Insomnia.
Wu X; Xue T; Chen Z; Wang Z; Chen G
Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
[TBL] [Abstract][Full Text] [Related]
6. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
[TBL] [Abstract][Full Text] [Related]
7. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
Han Y; Yuan K; Zheng Y; Lu L
Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.
Muehlan C; Vaillant C; Zenklusen I; Kraehenbuehl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1063-1078. PubMed ID: 32901578
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
Ziemichód W; Grabowska K; Kurowska A; Biała G
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
[TBL] [Abstract][Full Text] [Related]
10. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
11. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant.
Jha MK
Int J Neuropsychopharmacol; 2022 Jan; 25(1):85-88. PubMed ID: 34791262
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
Kumar A; Chanana P; Choudhary S
Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
[TBL] [Abstract][Full Text] [Related]
13. Orexin modulation of stress reactivity as a novel targeted treatment for anxiety and alcohol use disorder.
Gorka SM; Phan KL
Neuropsychopharmacology; 2022 Jan; 47(1):397-398. PubMed ID: 34341494
[No Abstract] [Full Text] [Related]
14. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
Tsuneki H; Wada T; Sasaoka T
Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
[TBL] [Abstract][Full Text] [Related]
15. Chronic orexin-1 receptor blockage attenuates depressive behaviors and provokes PSD-95 expression in a rat model of depression.
Mirbolouk B; Rohampour K; Rostampour M; Jafari A; Khakpour-Taleghani B
Behav Brain Res; 2023 Feb; 437():114123. PubMed ID: 36154849
[TBL] [Abstract][Full Text] [Related]
16. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment.
Palagini L; Geoffroy PA; Balestrieri M; Miniati M; Biggio G; Liguori C; Menicucci D; Ferini-Strambi L; Nobili L; Riemann D; Gemignani A
J Sleep Res; 2023 Aug; 32(4):e13825. PubMed ID: 36786121
[TBL] [Abstract][Full Text] [Related]
17. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
Skudlarek JW; DiMarco CN; Babaoglu K; Roecker AJ; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Wuelfing WP; Garson SL; Fox SV; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Kuduk SD; Coleman PJ
Bioorg Med Chem Lett; 2017 Mar; 27(6):1364-1370. PubMed ID: 28216403
[TBL] [Abstract][Full Text] [Related]
18. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.
James MH; Fragale JE; O'Connor SL; Zimmer BA; Aston-Jones G
Neuropharmacology; 2021 Feb; 183():108359. PubMed ID: 33091458
[TBL] [Abstract][Full Text] [Related]
19. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
Herring WJ; Roth T; Krystal AD; Michelson D
J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
[TBL] [Abstract][Full Text] [Related]
20. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target.
Gao F; Liu T; Tuo M; Chi S
Neurosci Lett; 2021 Nov; 765():136247. PubMed ID: 34530113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
